Gary E. Raskob

28.6k total citations · 16 hit papers
170 papers, 19.6k citations indexed

About

Gary E. Raskob is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Gary E. Raskob has authored 170 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Internal Medicine, 107 papers in Cardiology and Cardiovascular Medicine and 38 papers in Surgery. Recurrent topics in Gary E. Raskob's work include Venous Thromboembolism Diagnosis and Management (137 papers), Atrial Fibrillation Management and Outcomes (83 papers) and Acute Myocardial Infarction Research (30 papers). Gary E. Raskob is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (137 papers), Atrial Fibrillation Management and Outcomes (83 papers) and Acute Myocardial Infarction Research (30 papers). Gary E. Raskob collaborates with scholars based in United States, Canada and Netherlands. Gary E. Raskob's co-authors include Aaron M. Wendelboe, Russell D. Hull, Clive Kearon, Alexander Gallus, Graham F. Pineo, Giancarlo Agnelli, Jack Hirsh, Mark N. Levine, Seth Landefeld and Samuel Z. Goldhaber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Gary E. Raskob

166 papers receiving 18.7k citations

Hit Papers

Antithrombotic Therapy for Venous ... 1982 2026 1996 2011 2008 2012 2016 2009 2006 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Antithrombotic Therapy for Venous Thromboembolic Disease
    2008 1.4k citations Gary E. Raskob et al. profile →
  2. Apixaban for Extended Treatment of Venous Thromboembolism
    2012 918 citations Harry R. Büller, Alexander T. Cohen et al. profile →
  3. Global Burden of Thrombosis
    2016 904 citations Aaron M. Wendelboe, Gary E. Raskob Circulation Research profile →
  4. Pulmonary Arterial Hypertension
    2009 866 citations Gary E. Raskob, C. Gregory Elliott et al. profile →
  5. Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
    2006 862 citations Gary E. Raskob et al. profile →
  6. Hemorrhagic Complications of Anticoagulant Treatment
    2001 758 citations Gary E. Raskob et al. profile →
  7. Thrombosis
    2014 744 citations Gary E. Raskob, Pantep Angchaisuksiri et al. profile →
  8. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary E. Raskob et al. profile →
  9. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
    2010 603 citations Michael R. Lassen, Gary E. Raskob et al. profile →
  10. Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis
    1982 560 citations Gary E. Raskob et al. profile →
  11. Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis
    1986 560 citations Russell D. Hull, Gary E. Raskob et al. profile →
  12. Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
    1992 544 citations Russell D. Hull, Gary E. Raskob et al. profile →
  13. Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
    2009 529 citations Michael R. Lassen, Gary E. Raskob et al. profile →
  14. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
    2013 427 citations Gary E. Raskob et al. profile →
  15. Thrombosis: a major contributor to the global disease burden
    2014 344 citations Gary E. Raskob, Pantep Angchaisuksiri et al. Journal of Thrombosis and Haemostasis profile →
  16. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs
    2015 343 citations Lisa C. Richardson, Gary E. Raskob et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary E. Raskob United States 58 13.3k 11.1k 4.8k 3.2k 2.9k 170 19.6k
Walter Ageno Italy 67 13.7k 1.0× 11.4k 1.0× 4.0k 0.8× 3.6k 1.1× 1.8k 0.6× 557 20.5k
Menno V. Huisman Netherlands 76 20.0k 1.5× 15.5k 1.4× 5.8k 1.2× 3.2k 1.0× 3.2k 1.1× 469 29.6k
John A. Heit United States 68 23.7k 1.8× 15.2k 1.4× 9.3k 1.9× 6.5k 2.0× 3.2k 1.1× 220 30.9k
Richard H. White United States 61 8.5k 0.6× 5.5k 0.5× 4.0k 0.8× 2.6k 0.8× 2.1k 0.7× 242 15.9k
Susan R. Kahn Canada 70 20.3k 1.5× 11.5k 1.0× 10.0k 2.1× 4.2k 1.3× 2.1k 0.7× 330 25.8k
Sam Schulman Canada 69 21.5k 1.6× 21.5k 1.9× 7.1k 1.5× 7.7k 2.4× 2.1k 0.7× 501 34.5k
Giancarlo Agnelli Italy 63 11.6k 0.9× 9.3k 0.8× 3.5k 0.7× 1.9k 0.6× 2.3k 0.8× 335 16.4k
Stavros Konstantinides Germany 68 11.4k 0.9× 9.4k 0.8× 2.7k 0.6× 1.6k 0.5× 2.8k 1.0× 452 18.3k
Henri Bounameaux Switzerland 58 17.4k 1.3× 11.4k 1.0× 5.6k 1.2× 3.2k 1.0× 1.6k 0.5× 222 20.9k
Michael R. Lassen Denmark 36 13.4k 1.0× 11.4k 1.0× 4.9k 1.0× 2.0k 0.6× 1.4k 0.5× 129 16.8k

Countries citing papers authored by Gary E. Raskob

Since Specialization
Citations

This map shows the geographic impact of Gary E. Raskob's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Raskob with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Raskob more than expected).

Fields of papers citing papers by Gary E. Raskob

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Raskob. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Raskob. The network helps show where Gary E. Raskob may publish in the future.

Co-authorship network of co-authors of Gary E. Raskob

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Raskob. A scholar is included among the top collaborators of Gary E. Raskob based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Raskob. Gary E. Raskob is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Takada, Toshihiko, Floris T.M. Bosch, Andrea Marshall, et al.. (2024). Risk of Recurrent Venous Thromboembolism in Patients with Cancer: An Individual Patient Data Meta-analysis and Development of a Prediction Model. Thrombosis and Haemostasis. 125(6). 589–596. 2 indexed citations
2.
Spyropoulos, Alex C., Mark Goldin, Walter Ageno, et al.. (2022). Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. SHILAP Revista de lepidopterología. 6(3). e177–e183. 1 indexed citations
3.
Spyropoulos, Alex C., Gary E. Raskob, Theodore E. Spiro, et al.. (2022). Extended Thromboprophylaxis in Hospitalized Patients with Heart Failure: A Post Hoc Analysis of the MAGELLAN Study. SHILAP Revista de lepidopterología. 6(4). e304–e308.
4.
Raskob, Gary E., Walter Ageno, Gregory W. Albers, et al.. (2022). Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association. 11(20). e026229–e026229. 7 indexed citations
5.
Raskob, Gary E., Aaron M. Wendelboe, Janis E. Campbell, et al.. (2022). Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population. Journal of Thrombosis and Haemostasis. 20(10). 2366–2378. 8 indexed citations
6.
Spyropoulos, Alex C., Gary E. Raskob, Alexander T. Cohen, et al.. (2022). Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation. 145(19). 1471–1479. 5 indexed citations
7.
8.
Lipardi, Concetta, C. Gregory Elliott, Lloyd Haskell, et al.. (2021). Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis. Clinical and Applied Thrombosis/Hemostasis. 27. 2975234820–2975234820. 1 indexed citations
9.
Raskob, Gary E., Alex C. Spyropoulos, Alexander T. Cohen, et al.. (2021). Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association. 10(5). e019459–e019459. 20 indexed citations
10.
Spyropoulos, Alex C., Concetta Lipardi, Eunyoung Suh, et al.. (2019). Improved Benefit Risk Profile of Rivaroxaban in a Subpopulation of the MAGELLAN Study. Clinical and Applied Thrombosis/Hemostasis. 25. 2873284550–2873284550. 46 indexed citations
11.
Mulder, Frits I., Marcello Di Nisio, Cihan Ay, et al.. (2019). Clinical implications of incidental venous thromboembolism in cancer patients. European Respiratory Journal. 55(2). 1901697–1901697. 31 indexed citations
12.
Raskob, Gary E., Alex C. Spyropoulos, Alexander T. Cohen, et al.. (2019). Abstract 12863: Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis of Mortality and Major Thromboembolic Events in 16,496 Patients From the MAGELLAN and MARINER Trials. Circulation. 3 indexed citations
13.
Spyropoulos, Alex C., Alexander T. Cohen, Concetta Lipardi, et al.. (2018). Abstract 10541: Improved Benefit Risk Profile of Rivaroxaban in a MARINER-Like Subpopulation of the MAGELLaN Study. Circulation. 1 indexed citations
14.
Wendelboe, Aaron M. & Gary E. Raskob. (2016). Global Burden of Thrombosis. Circulation Research. 118(9). 1340–1347. 904 indexed citations breakdown →
15.
Raskob, Gary E., Harry R. Büller, Pantep Angchaisuksiri, et al.. (2013). Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients. Blood. 122(21). 211–211. 18 indexed citations
16.
Raskob, Gary E., Alexander Gallus, Graham F. Pineo, et al.. (2012). Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement. Journal of Bone and Joint Surgery - British Volume. 94-B(2). 257–264. 72 indexed citations
17.
Hull, Russell D., Graham F. Pineo, Paul D. Stein, et al.. (2001). Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty. Annals of Internal Medicine. 1 indexed citations
18.
Tapson, Victor F., B A Carroll, Bruce L. Davidson, et al.. (1999). The Diagnostic Approach to Acute Venous Thromboembolism: Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 160(3). 1043–1066. 225 indexed citations
19.
Langer, Anatoly, Gary E. Raskob, Richard J. Gray, et al.. (1994). Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. The American Journal of Cardiology. 74(7). 657–661. 16 indexed citations
20.
Hull, Russell D., Gary E. Raskob, Graham F. Pineo, et al.. (1992). Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis. Obstetrical & Gynecological Survey. 47(9). 620–622. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Walter Ageno Breakdown of academic impact, for papers by Menno V. Huisman Breakdown of academic impact, for papers by John A. Heit Breakdown of academic impact, for papers by Richard H. White Breakdown of academic impact, for papers by Susan R. Kahn Breakdown of academic impact, for papers by Sam Schulman Breakdown of academic impact, for papers by Giancarlo Agnelli Breakdown of academic impact, for papers by Stavros Konstantinides Breakdown of academic impact, for papers by Henri Bounameaux Breakdown of academic impact, for papers by Michael R. Lassen
Rankless by CCL
2026